Merck & Co Inc Stock (MRK) Moved Up by 4.09% on May 1: Key Drivers Unveiled

Merck & Co Inc (MRK) moved up by 4.09%. The Pharmaceuticals & Medical Research sector is up by 0.25%. The company outperformed the industry. Top 3 stocks by turnover in the sector: Eli Lilly and Co (LLY) up 4.44%; Esperion Therapeutics Inc (ESPR) up 55.50%; Merck & Co Inc (MRK) up 4.09%.

What is driving Merck & Co Inc (MRK)’s stock price up today?

Merck & Co. (MRK) experienced significant upward intraday movement, primarily driven by its robust first-quarter 2026 financial results and an optimistic outlook for the remainder of the year. The company surpassed analyst expectations on both revenue and adjusted earnings per share. Merck reported first-quarter revenues of $16.29 billion, exceeding estimates. While the company posted a net loss, its adjusted loss per share of $1.28 was narrower than the anticipated $1.52 loss, suggesting better operational performance than projected.

A key factor contributing to investor confidence was the strong performance of Merck's core products. Sales of its oncology blockbuster, KEYTRUDA, saw an 8% increase when excluding foreign exchange impacts, reaching $8.03 billion, indicating sustained demand in cancer treatments. Additionally, WINREVAIR, a newer product, demonstrated impressive growth with sales surging 88% to $525 million, reflecting rapid market uptake. The Animal Health segment also contributed positively with a 6% growth in sales, excluding foreign exchange.

Further bolstering the positive sentiment, Merck raised and narrowed its full-year 2026 financial guidance. The company now anticipates revenues to be between $65.8 billion and $67.0 billion, an increase from its previous lower-end estimate. Similarly, the adjusted earnings per share outlook was raised to a range of $5.04 to $5.16. This revised guidance signals a more confident outlook from management regarding future performance.

Recent major events also played a role, notably the U.S. Food and Drug Administration's (FDA) approval of IDVYNSO, a new once-daily regimen for HIV-1 infection, which is expected to expand Merck's therapeutic offerings. The company also highlighted its portfolio transformation initiatives, including strategic partnerships aimed at enhancing its pipeline and future growth drivers. Although the company incurred a significant one-time charge related to an acquisition, the market's focus appears to be on the underlying strength of the business and its promising pipeline.

Technical Analysis of Merck & Co Inc (MRK)

Technically, Merck & Co Inc (MRK) shows a MACD (12,26,9) value of [-1.27], indicating a sell signal. The RSI at 34.64 suggests neutral condition and the Williams %R at -90.45 suggests oversold condition. Please monitor closely.

Media Coverage of Merck & Co Inc (MRK)

In terms of media coverage, Merck & Co Inc (MRK) shows a coverage score of 49, indicating a moderate level of media attention. The overall market sentiment index is currently in bullish zone.

Fundamental Analysis of Merck & Co Inc (MRK)

Merck & Co Inc (MRK) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $65.01B, ranking 5 in the industry. The net profit is $18.25B, ranking 3 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Buy, with an average price target of $129.46, a high of $150.00, and a low of $100.00.

More details about Merck & Co Inc (MRK)

Company Specific Risks:

• Merck reported a GAAP loss in Q1/2026 due to an acquisition-related charge (Cidara), coupled with tightened 2026 sales guidance, signaling potential financial headwinds and reduced top-line visibility.
• The upcoming patent expiry of Keytruda in 2028 poses a significant long-term growth challenge, with analysts expressing concerns about the company's future sales profile and investment strategies to offset this impact.
• A substantial decline in Gardasil vaccine sales, particularly due to halted shipments to China, indicates potential market access issues and risks to brand reputation in crucial international markets.
• Merck projects a $200 million financial loss in 2025 from tariffs stemming from US-China trade tensions, representing an ongoing regulatory and market risk impacting profitability.